Literature DB >> 31232114

Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14).

Guido Ghilardi1, Georg Stussi1, Luca Mazzucchelli2, Christoph Röcken3, Davide Rossi1, Bernhard Gerber1.   

Abstract

Entities:  

Year:  2019        PMID： 31232114     DOI： 10.1080/13506129.2019.1615428

Source DB:  PubMed          Journal:  Amyloid        ISSN： 1350-6129            Impact factor:   7.141


× No keyword cloud information.
  6 in total

Review 1.  Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021.

Authors:  M Hasib Sidiqi; Morie A Gertz
Journal:  Blood Cancer J       Date:  2021-05-15       Impact factor: 11.037

2.  Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.

Authors:  Vikram J Premkumar; Suzanne Lentzsch; Samuel Pan; Divaya Bhutani; Joshua Richter; Sundar Jagannath; Michaela Liedtke; Arnaud Jaccard; Ashutosh D Wechalekar; Raymond Comenzo; Vaishali Sanchorawala; Bruno Royer; Michael Rosenzweig; Jason Valent; Stefan Schönland; Rafael Fonseca; Sandy Wong; Prashant Kapoor
Journal:  Blood Cancer J       Date:  2021-01-11       Impact factor: 11.037

3.  Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics.

Authors:  Cameron S Fraser; Johan K E Spetz; Xingping Qin; Adam Presser; Jonathan Choiniere; Chendi Li; Stacey Yu; Frances Blevins; Aaron N Hata; Jeffrey W Miller; Gary A Bradshaw; Marian Kalocsay; Vaishali Sanchorawala; Shayna Sarosiek; Kristopher A Sarosiek
Journal:  Nat Commun       Date:  2022-10-02       Impact factor: 17.694

Review 4.  Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications.

Authors:  Linchun Xu; Yongzhong Su
Journal:  Exp Hematol Oncol       Date:  2021-07-20

Review 5.  Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis.

Authors:  Giovanni Palladini; Paolo Milani; Fabio Malavasi; Giampaolo Merlini
Journal:  Cells       Date:  2021-03-04       Impact factor: 6.600

6.  Daratumumab in AL Amyloidosis: A Real-Life Experience of the "RTM" (Regional Tuscan Myeloma Network).

Authors:  Vincenzo Sammartano; Elisabetta Antonioli; Gabriele Buda; Sara Ciofini; Veronica Candi; Ludovica Pengue; Maria Livia Del Giudice; Irene Attucci; Francesca Bacchiarri; Ubaldo Occhini; Maria Teresa Pirrotta; Federico Perfetto; Monica Bocchia; Alessandro Gozzetti
Journal:  J Pers Med       Date:  2022-03-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.